Neoadjuvant Therapy

• 

  Subject Areas on Research

  • 3D image guidance assisted identification of colorectal cancer liver metastases not seen on intraoperative ultrasound: results from a prospective trial. 
  • A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial. 
  • A Minimally Invasive Approach to Lobectomy After Induction Therapy Does Not Compromise Survival. 
  • A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence. 
  • A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. 
  • A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. 
  • A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. 
  • A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. 
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. 
  • A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. 
  • ASO Author Reflections: Entering the Era of Biomarker-Driven Management of the Axilla. 
  • ASO Author Reflections: Molecular Signatures May Render Surgical Staging of the Axilla Obsolete. 
  • ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). 
  • Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. 
  • Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. 
  • Adjuvant Chemotherapy After Preoperative Chemoradiation Improves Survival in Patients With Locally Advanced Rectal Cancer. 
  • Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. 
  • Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. 
  • Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. 
  • Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study. 
  • Adjuvant therapy of pancreatic cancer. 
  • Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. 
  • Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. 
  • Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. 
  • Applying the neoadjuvant paradigm to ductal carcinoma in situ. 
  • Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. 
  • Are we choosing wisely? Drivers of preoperative MRI use in breast cancer patients. 
  • Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. 
  • Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). 
  • Assessment of multimodality therapy use for extremity sarcoma in the United States. 
  • Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer. 
  • Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. 
  • Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. 
  • Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. 
  • Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. 
  • Bladder cancer. Clinical guidelines in oncology. 
  • Breast cancer in young women: Imaging and clinical course. 
  • Breast cancer. Clinical practice guidelines in oncology. 
  • CT-derived body composition measurements as predictors for neoadjuvant treatment tolerance and survival in gastroesophageal adenocarcinoma. 
  • Can surgeons improve survival in stage IV melanoma? 
  • Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. 
  • Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. 
  • Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer. 
  • Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectum. 
  • Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. 
  • Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma. 
  • Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. 
  • Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. 
  • Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface. 
  • Chemotherapy-induced splenic volume increase is independently associated with major complications after hepatic resection for metastatic colorectal cancer. 
  • Chronic myelogenous leukemia. 
  • Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. 
  • Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review. 
  • Colon cancer. 
  • Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment. 
  • Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. 
  • Combined-modality therapy for rectal cancer: future prospects. 
  • Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. 
  • Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. 
  • Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. 
  • Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis. 
  • Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage. 
  • Controversial issues regarding the use of induction chemotherapy for lung cancer. 
  • Cost-Effectiveness of Venous Thromboembolism Prophylaxis During Neoadjuvant Chemotherapy for Ovarian Cancer. 
  • Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. 
  • Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. 
  • Current and future cancer staging after neoadjuvant treatment for solid tumors. 
  • DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study. 
  • DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. 
  • Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting. 
  • Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. 
  • Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases. 
  • Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. 
  • Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are < or = 1 cm distal margins sufficient? 
  • Does computed tomography or positron emission tomography response after neoadjuvant chemotherapy for resectable non-small-cell lung cancer predict survival? 
  • Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? 
  • Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? 
  • Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. 
  • Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. 
  • Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. 
  • Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. 
  • Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. 
  • Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation. 
  • Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. 
  • Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. 
  • Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. 
  • Equivalent Treatment and Survival after Resection of Pancreatic Cancer at Safety-Net Hospitals. 
  • Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. 
  • Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial. 
  • Evaluation of the Axillary Surgery Performed in Clinically Node-Positive Breast Cancer Patients Following Neoadjuvant Chemotherapy. 
  • Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. 
  • Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection. 
  • Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. 
  • Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. 
  • Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. 
  • Factors Affecting Time to Surgery in Breast Cancer Patients. 
  • Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). 
  • Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). 
  • Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. 
  • Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. 
  • Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. 
  • Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. 
  • HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. 
  • Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism. 
  • Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. 
  • Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). 
  • ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. 
  • Immediate Breast Reconstruction Allows for the Timely Initiation of Postmastectomy Radiation Therapy. 
  • Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. 
  • Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. 
  • Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. 
  • Impact of time duration after neoadjuvant therapy to surgery on response and outcome in rectal cancer patients. 
  • Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. 
  • Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. 
  • Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. 
  • Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. 
  • Increasing use of positron emission tomography among medicare beneficiaries undergoing radical cystectomy. 
  • Induction Therapy or Upfront Surgery? The Debate Rages On: Reply. 
  • Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. 
  • Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). 
  • Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. 
  • Induction chemotherapy: to use or not to use? That is the question. 
  • Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. 
  • Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). 
  • Initial experience with neoadjuvant FOLFIRINOX as first line therapy for locally advanced pancreatic cancer. 
  • Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. 
  • Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer. 
  • Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. 
  • Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy. 
  • Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • It's not always too late: a case for minimally invasive salvage esophagectomy. 
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). 
  • LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. 
  • Leukocyte composition of human breast cancer. 
  • Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. 
  • Liver transplantation for hilar cholangiocarcinoma: A systematic review. 
  • Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. 
  • Local excision of rectal cancer revisited: ACOSOG protocol Z6041. 
  • Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. 
  • Locally unresectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration. 
  • Long-term Oncologic Outcomes After Neoadjuvant Radiation Therapy for Retroperitoneal Sarcomas. 
  • Long-term outcomes following microwave ablation for liver malignancies. 
  • Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. 
  • Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. 
  • Long-term survival following open versus thoracoscopic lobectomy after preoperative chemotherapy for non-small cell lung cancer. 
  • Low morbidity and mortality for bronchoplastic procedures with and without induction therapy. 
  • Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. 
  • MRI Evaluation of the Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy. 
  • MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. 
  • MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. 
  • Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. 
  • Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. 
  • Management of Locoregional Rectal Cancer. 
  • Management of resectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Matrix compliance permits NF-κB activation to drive therapy resistance in breast cancer. 
  • Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. 
  • Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. 
  • Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
  • Multi-institutional Care in Clinical Stage II and III Esophageal Cancer. 
  • Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. 
  • Multidisciplinary management of locally advanced rectal cancer: neoadjuvant approaches. 
  • Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment. 
  • Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. 
  • NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. 
  • NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. 
  • NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. 
  • NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. 
  • Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. 
  • Neck dissection followed by chemoradiotherapy for stage IV (N+) oropharynx cancer. 
  • Neoadjuvant Chemotherapy Shifts Breast Tumor Microbiota Populations to Regulate Drug Responsiveness and the Development of Metastasis. 
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. 
  • Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. 
  • Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma. 
  • Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. 
  • Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. 
  • Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens. 
  • Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 
  • Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. 
  • Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. 
  • Neoadjuvant hormone therapy: the Canadian trials. 
  • Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States. 
  • Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer. 
  • Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. 
  • Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. 
  • Neoadjuvant use of ipilimumab in locally advanced melanoma. 
  • New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. 
  • No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database. 
  • Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis. 
  • Nonoperative management of rectal cancer. 
  • Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. 
  • Novel approaches to 'borderline resectable' pancreatic tumors. 
  • Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. 
  • Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. 
  • Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. 
  • Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. 
  • Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management. 
  • Ovarian cancer, version 3.2012. 
  • PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. 
  • Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. 
  • Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. 
  • Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. 
  • Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. 
  • Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. 
  • Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy. 
  • Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. 
  • Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. 
  • Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. 
  • Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study. 
  • Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. 
  • Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. 
  • Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. 
  • Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer. 
  • Patterns and Impact of Fragmented Care in Stage II and III Gastric Cancer. 
  • Patterns of Care in Neoadjuvant Chemoradiotherapy for Node-Positive Esophageal Adenocarcinoma. 
  • Patterns of recurrence after ablation of colorectal cancer liver metastases. 
  • Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. 
  • Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. 
  • Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer. 
  • Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. 
  • Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer. 
  • Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). 
  • Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. 
  • Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. 
  • Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. 
  • Photodynamic therapy provides local control of cholangiocarcinoma in patients awaiting liver transplantation. 
  • Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. 
  • Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. 
  • Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. 
  • Prediction model to estimate overall survival benefit of postoperative radiotherapy for resected major salivary gland cancers. 
  • Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. 
  • Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. 
  • Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). 
  • Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). 
  • Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. 
  • Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. 
  • Preoperative chemoradiotherapy for locally advanced gastric cancer. 
  • Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 
  • Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. 
  • Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. 
  • Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: Should lymph node retrieval guidelines be altered? 
  • Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. 
  • Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer. 
  • Primary treatment of advanced ovarian cancer: how does the 'real world' practice? 
  • Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. 
  • Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer. 
  • Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. 
  • Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. 
  • Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. 
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. 
  • Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. 
  • Radiation Therapy for Soft Tissue Sarcoma: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy. 
  • Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. 
  • Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. 
  • Re: Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. 
  • Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. 
  • Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Reducing hospital morbidity and mortality following esophagectomy. 
  • Resected irradiated rectal cancers: Are twelve lymph nodes really necessary in the era of neoadjuvant therapy? 
  • Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy. 
  • Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection? 
  • Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. 
  • Response to Mroczkowski. 
  • Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. 
  • Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. 
  • Right-Sided Versus Left-Sided Pneumonectomy After Induction Therapy for Non-Small Cell Lung Cancer. 
  • Risk factors for surgical site infections after breast surgery: a systematic review and meta-analysis. 
  • Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. 
  • Role of radiation therapy in patients with resectable pancreatic cancer. 
  • SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study. 
  • Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies. 
  • Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. 
  • Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. 
  • Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. 
  • Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. 
  • Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. 
  • Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. 
  • Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis. 
  • Short-course versus long-course chemoradiation in rectal cancer--time to change strategies? 
  • Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. 
  • Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. 
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. 
  • Stage III lung cancer: two or three modalities? The continued role of thoracic radiotherapy. 
  • Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis. 
  • Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer. 
  • Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. 
  • Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. 
  • Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. 
  • Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival? 
  • Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing? 
  • Surgical strategies and outcomes after induction therapy for non-small cell lung cancer. 
  • Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis. 
  • Survival outcomes in sinonasal carcinoma with neuroendocrine differentiation: A NCDB analysis. 
  • Swallowing Function Following Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Carcinoma: A 2-Year Follow-up. 
  • Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. 
  • Systemic chemotherapy for urothelial cancer. 
  • Systemic therapy for prostate cancer. 
  • TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. 
  • TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). 
  • Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response. 
  • Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak. 
  • Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. 
  • Targeted Neoadjuvant Intra-arterial Chemotherapy in Lacrimal Gland Adenoid Cystic Carcinoma: A Histological Correlation Using Apoptotic Tumor Markers. 
  • Targeted therapy in rectal cancer. 
  • Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. 
  • Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma. 
  • The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. 
  • The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB). 
  • The Comparison of Surgical Approaches in Locally Advanced Esophageal Cancer: Significant Insights but Clinical Fidelity Still to Be Delivered. 
  • The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. 
  • The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. 
  • The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis. 
  • The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials. 
  • The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. 
  • The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. 
  • The effect of neoadjuvant radiation therapy on perioperative outcomes among patients undergoing resection of retroperitoneal sarcomas. 
  • The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. 
  • The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? 
  • The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma. 
  • The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. 
  • The impact of pre-radiotherapy surgery on radiation-induced lung injury. 
  • The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. 
  • The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. 
  • The role of individualized treatment in patients with oesophageal cancer: mind the patient and not only the disease. 
  • The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy. 
  • Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. 
  • Thirty years of rectal cancer research: a brief history. 
  • Thymoma: benign appearance, malignant potential. 
  • Time for a neoadjuvant chemotherapy strategy in prostate cancer? 
  • Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer. 
  • Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. 
  • Total neoadjuvant therapy for rectal cancer: An emerging option. 
  • Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. 
  • Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. 
  • Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. 
  • Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study. 
  • Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. 
  • Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. 
  • Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. 
  • Utility of Image Guidance in the Localization of Disappearing Colorectal Liver Metastases. 
  • Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer. 
  • Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. 
  • Value of surgical resection in children with high-risk neuroblastoma. 
  • Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival. 
  • Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches. 
  • Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. 
  • What's new in neoadjuvant therapy for breast cancer? 
  • [Femur reconstruction using combined autologous fibula transfer and humeral allograft]. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Distinguished Professor of Medical Oncology, Medicine, Medical Oncology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology